about
Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPPA 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute.Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT).Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole.Medulloblastoma in adults: clinical characteristics and treatment.Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma.The treatment of cranial germ cell tumours.Temozolomide in patients with high grade gliomas.High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.Management of small-cell lung cancer in the elderly.Oxaliplatin-related neurotoxicity: how and why?BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer.Prescribing anti-cancer drugs in elderly cancer patients.Is there a role for chemoradiotherapy in the treatment of pancreatic carcinoma?The epidemiology of acquired immunodeficiency syndrome and associated tumours in Europe.Recommendations for the management of malignant gliomas in the elderly.Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.Old and new drugs in systemic therapy of pancreatic cancer.Treatment options for early breast cancer in elderly women.Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.Neoadjuvant treatment for locally advanced rectal carcinoma.Management of muscle-invasive bladder cancer in the elderly.Multidimensional geriatric evaluation in elderly cancer patients: a practical approach.Treatments of AIDS-related Kaposi's sarcoma.Treatment of stage IV colorectal carcinoma in elderly patients.Colorectal cancer adjuvant treatment in elderly patients.Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).The development of platinum compounds and their possible combination.Supportive care in patients with advanced non-small-cell lung cancer.Induction intra-arterial cisplatin and bleomycin in head and neck cancer.Gemcitabine in advanced biliary tract cancers.Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses.Quality of life in elderly cancer patients.Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.Oral anticancer drugs in the elderly: an overview.
P50
Q28252682-62A68D65-634C-45D5-9F9F-AB2AE327A7E8Q31884495-5511B81C-5BD4-4578-A3BB-3DA14A63C832Q33337168-5807E1FF-EEFE-4E44-9231-9EB39C4B2673Q33348171-D45577AD-C2FA-42B2-99BF-57387837A5DDQ33357716-C44F5A7A-BD59-47E5-8590-49C9BEA747E9Q33360637-8ABE0F48-9189-4627-B903-A53758317C74Q33487804-E5292CF6-E812-431C-B85A-452481063C56Q33502196-F4942FED-F295-47FC-87BF-5627B2422DFDQ33599122-1B97CDE9-4E89-4316-BC0C-4AF747C58858Q33900899-311F0B29-4BC3-45B5-A906-EFB04013DE78Q33982788-DCF72560-F7AA-446F-BA4A-359C652F30CBQ34071655-61971CA1-281E-4694-B635-69029CA1989BQ34211011-2A3346A5-1336-4BAB-B8D0-BCEB79440113Q34498108-DD98AC94-E897-4D2B-A2B4-48EE20DC26B7Q34542694-AE3E807B-1FDB-445F-89AB-4E7CDDB3DFA5Q34548207-54D85C6A-F709-49A0-81FD-2D5281E50B12Q34654711-A0A72456-EF06-42C8-9165-A9E9E5A04BE7Q35013560-D229BFCA-0873-4685-B8C6-180F868613D1Q35202575-28B588DB-EB7F-418E-A372-6BB6E2F4C45CQ35538639-67FD74CA-E9DD-43B8-926E-D59C3C953AD8Q35576169-06ED8EDA-4338-4F19-9B7B-9962E922DC55Q35673265-8B63B159-3393-453E-BC8D-58A921AAEF29Q35687705-C7ECD754-04C7-4C4E-9657-A6DDA5CFE937Q35728668-4D4AF342-4AA2-4959-89A4-8C9EDB328077Q35872199-12EBAE43-AE53-41CA-9F96-207A1347750EQ35885328-E1F7BE1C-B3B0-4A9F-966E-F75AB9904229Q35987747-7932DC1C-73C8-4046-90F9-2BD2BD6F5F1AQ35987994-858D24ED-006D-4FF4-9784-615973CF6218Q36046535-61243DD7-1914-43EE-B917-2738FB81C3FCQ36103271-D3854C0B-6A63-4635-9E14-F847551C85B6Q36204766-FFC41587-654A-458B-A341-0FE9E31A2019Q36220834-1CA71806-F461-4903-B4D3-9019D0581F65Q36522448-EAE81EA8-1C3A-4507-A711-A51299B8FF13Q36648391-50BCDD39-D0FA-44EF-B675-9FB069582C67Q36672983-F033184C-B1F2-4A3B-9129-9D61C569AA1DQ36678152-8DE10750-6612-4B62-B684-3AA0ACEDC96EQ36709779-BA0FB64B-6CA0-4F2C-827F-171DD40E3113Q36733205-410FC079-C239-4309-A769-39E620D1DBA4Q36789292-ABD52F77-2693-41AB-8BDC-973B3EF3C155Q36822388-68C9305B-BB14-4E1B-B5BA-E849F3BEBBD6
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Silvio Monfardini
@ast
Silvio Monfardini
@en
Silvio Monfardini
@es
Silvio Monfardini
@nl
type
label
Silvio Monfardini
@ast
Silvio Monfardini
@en
Silvio Monfardini
@es
Silvio Monfardini
@nl
prefLabel
Silvio Monfardini
@ast
Silvio Monfardini
@en
Silvio Monfardini
@es
Silvio Monfardini
@nl
P214
P106
P1153
7103008217
P21
P214
P31
P496
0000-0002-9130-3896
P7859
lccn-n82038314